牛牛AI助理已提取核心訊息
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended report (Form 8-K/A) with the Securities and Exchange Commission (SEC) on January 9, 2024. The amendment provides updates on costs associated with the company's exit activities from a portion of its Foster City campus. Initially reported on June 26, 2023, and subsequently amended on November 13, 2023, the company has now estimated impairment charges of approximately $43 million for the fourth fiscal quarter of 2023. These charges are related to right-of-use asset and leasehold improvement impairments. Illumina continues to evaluate options for the remaining parts of its Foster City campus and may incur additional charges, the extent of which cannot be currently estimated. The company has stated that these charges will be excluded from its non-GAAP financial metrics and will file further amendments if the costs are material and estimable. The report also includes forward-looking statements with the usual caveats regarding the risks and uncertainties associated with such predictions.
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended report (Form 8-K/A) with the Securities and Exchange Commission (SEC) on January 9, 2024. The amendment provides updates on costs associated with the company's exit activities from a portion of its Foster City campus. Initially reported on June 26, 2023, and subsequently amended on November 13, 2023, the company has now estimated impairment charges of approximately $43 million for the fourth fiscal quarter of 2023. These charges are related to right-of-use asset and leasehold improvement impairments. Illumina continues to evaluate options for the remaining parts of its Foster City campus and may incur additional charges, the extent of which cannot be currently estimated. The company has stated that these charges will be excluded from its non-GAAP financial metrics and will file further amendments if the costs are material and estimable. The report also includes forward-looking statements with the usual caveats regarding the risks and uncertainties associated with such predictions.
總部位於加利福尼亞州聖地亞哥的生物技術公司Illumina, Inc. 已於2024年1月9日向美國證券交易委員會 (SEC) 提交了修訂報告（表格8-K/A）。該修正案提供了與該公司從福斯特城部分園區退出活動相關的費用的最新情況。該公司最初於2023年6月26日報告，隨後於2023年11月13日進行了修訂，現在估計2023年第四財季的減值費用約爲4,300萬美元。這些費用與使用權資產和租賃權益改善減值有關。Illumina繼續評估其福斯特城校區其餘部分的備選方案，可能會產生額外費用，其範圍目前無法估計。該公司表示，這些費用將不包括在其非公認會計准則財務指標中，如果成本是重大且可估算的，則將提出進一步的修正。該報告還包括前瞻性陳述，並附有與此類預測相關的風險和不確定性的常見注意事項。
總部位於加利福尼亞州聖地亞哥的生物技術公司Illumina, Inc. 已於2024年1月9日向美國證券交易委員會 (SEC) 提交了修訂報告（表格8-K/A）。該修正案提供了與該公司從福斯特城部分園區退出活動相關的費用的最新情況。該公司最初於2023年6月26日報告，隨後於2023年11月13日進行了修訂，現在估計2023年第四財季的減值費用約爲4,300萬美元。這些費用與使用權資產和租賃權益改善減值有關。Illumina繼續評估其福斯特城校區其餘部分的備選方案，可能會產生額外費用，其範圍目前無法估計。該公司表示，這些費用將不包括在其非公認會計准則財務指標中，如果成本是重大且可估算的，則將提出進一步的修正。該報告還包括前瞻性陳述，並附有與此類預測相關的風險和不確定性的常見注意事項。
有用
沒用